|
|
|
11-50 employees
View all Aeglea BioTherapeutics employees
|
|
Biotechnology
|
|
805 Las Cimas Pkwy, Suite 100, Austin, Texas 78746, US
|
|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
For more information, please visit http://aeglea.com.
|
David G Lowe is the CEO of Aeglea BioTherapeutics. To contact David G Lowe email at [email protected]. Or you may call +1.5129422935
The decision makers in Aeglea BioTherapeutics are Allison Motal Trucillo, Dan Godoy, David G Lowe, etc. Click to Find Aeglea BioTherapeutics decision makers emails.
You can reach out to Aeglea BioTherapeutics through their official website's contact form or by emailing their customer service team. For specific inquiries, including partnerships or collaborations, consider reaching out directly to the relevant department listed on their website.
Aeglea BioTherapeutics does not publicly list a detailed staff directory. However, key personnel and leadership information can typically be found on their website under the 'Our Team' section, providing insights into their expertise and roles within the company.
Aeglea BioTherapeutics primarily focuses on the biotechnology industry, with a strong emphasis on developing treatments for rare diseases, particularly inflammatory bowel disease (IBD). Their innovative approaches include engineering human enzymes and antibody therapies to enhance treatment efficacy.
Aeglea BioTherapeutics specializes in developing biopharmaceuticals for rare diseases, utilizing advanced enzyme engineering and precision immunology. Their services include research and development of therapies aimed at improving patient outcomes in conditions like inflammatory bowel disease (IBD).
Aeglea BioTherapeutics employs rigorous research methodologies, including best-in-class antibody engineering and rational therapeutic combinations. Their commitment to precision immunology ensures that treatments are tailored for maximum efficacy and safety, particularly for patients with inflammatory bowel disease (IBD).
Aeglea BioTherapeutics welcomes potential collaborations in research and development. Interested parties should contact the company directly through their website's contact page to discuss opportunities and outline potential projects that align with their focus on rare diseases and innovative therapies.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.